VILDAPHAGE M® and VILDAPHAGE M FORTE® Tablets

No Image Found
Composition:

VILDAPHAGE M®: 


Each film coated tablets contains:

  • Vildagliptin ……………………………..……….. 50 mg
  • Metformin Hydrochloride ………… 500 mg

  • Excipients ………………………………….…….…. q.s.

     

VILDAPHAGE M FORTE®:

Each film coated tablets contains:

  • Vildagliptin ………………………………………….. 50 mg
  • Metformin Hydrochloride ……………. 1000 mg
  • Excipients …………………………………….……..... q.s.

Description

  • Combines two Anti-diabetic medications with complementary mechanisms of action to improve glycaemic control in adults with type 2 diabetes.
  • Vildagliptin is a DPP-4 inhibitor and Metformin Hydrochloride belongs to the biguanide class of drugs. 
  • Metformin activates AMP-activated protein kinase (AMPK), a liver enzyme and thereby inhibits glucose production by liver.

Indications

  • For patients of age 18 years and above with Type 2 diabetes mellitus (T2DM) VILDAPHAGE-M / VILDAPHAGE-M FORTE is indicated
  • In combination with a sulfonylurea (SU) (i.e., triple combination therapy)
  • As add-on to insulin, in patients when stable doses of insulin and metformin alone do not provide adequate glycemic control.
  • In T2DM patients having HbA1c > 8% where diabetes is not adequately controlled by diet and exercise alone.